Imaging Mass Spectrometry Reveals Elevated Nigral Levels of Dynorphin Neuropeptides in L-DOPA-Induced Dyskinesia in Rat Model of Parkinson's Disease

When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease

(2010) Fabrizio Stocchi et al.   EUROPEAN NEUROLOGY

Analysis of mouse brain peptides using mass spectrometry-based peptidomics: implications for novel functions ranging from non-classical neuropeptides to microproteins

(2010) Lloyd D. Fricker   Molecular BioSystems

Levodopa in the treatment of Parkinson’s disease

(2009) A. H. V. Schapira et al.   EUROPEAN JOURNAL OF NEUROLOGY

De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat

(2009) Michèle El Atifi-Borel et al.   NEUROBIOLOGY OF DISEASE

Mechanisms compensating for dopamine loss in early Parkinson disease

(2009) J. Brotchie et al.   NEUROLOGY

30 years of dynorphins — New insights on their functions in neuropsychiatric diseases

(2009) Christoph Schwarzer   PHARMACOLOGY & THERAPEUTICS

Imaging mass spectrometry of proteins and peptides: 3D volume reconstruction

(2007) Malin Andersson et al.   NATURE METHODS